1Frank DN, St Amand AL, Feldman RA, et al. (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. PNAS 104, 13780–13785.
2World Health Organization (1946) .
3World Health Organization (2006) .
4Volponi AJ, Broteron T & Luppold R (2004) .
5Zhao L & Shen J (2010) Whole-body systems approaches for gut-microbiota-targeted, preventive healthcare. J Biotechnol 149, 183–190.
6Zeissig S, Bojarski C, Buergel N, et al. (2004) Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment. Gut 53, 1295–1302.
7Hering NA, Fromm A, van Tol EA, et al. (2010) Transforming growth factor-α, a whey protein component, strengthens the intestinal barrier by upregulating claudin-4 in HT/29/B6 cells. J Nutr 141, 783–789.
8Amasheh M, Schlicter S, Amasheh S, et al. (2008) Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells. J Nutr 138, 1067–1073.
9Amasheh M, Fromm A, Krug SM, et al. (2010) TNF-α induced and berberine-antagonized tight junction barrier impairment via tyrosine kinas, Akt and NFκB signalling. J Cell Science 123, 4145–4155.
10Raes J & Bork P (2008) Molecular eco-systems biology: towards a better understanding of community function. Nat Rev Microbiol 6, 693–699.
11Turnbaugh PJ, Ley RE, Hamady M, et al. (2007) The human microbiome project. Nature 449, 804–810.
12Qin J, Li R, Raes J, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65.
13Arumugam M, Raes J, Pelletier E, et al. (2011) Enterotypes of the human gut microbiome. Nature 473, 174–180, .
14Zwielehner J, Liszt K, Handschur M, et al. (2009) Combined PCR-DGGE fingerprinting and quantitative-PCR indicates shifts in fecal population sizes and diversity of Bacteroides, bifidobacteria and Clostridium cluster IV in institutionalized elderly. Exp Gerontol 44, 440–446.
15Liszt K, Zwielehner J, Handschur M, et al. (2009) Characterization of bacteria, clostridia and Bacteroides in faeces of vegetarians using qPCR and PCR-DGGE fingerprinting. Ann Nutr Metab 54, 253–257.
16Greer JB & O'Keefe SJ (2011) Microbial induction of immunity, inflammation, and cancer. Front Physiol 1, 168.
17Zoetendal EG, Akkermans ADL & de Vos WM (1998) Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 64, 3854–3859.
18Walker AW, Ince J, Duncan SH, et al. (2011) Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 5, 220–230.
19Duncan SH, Belenguer A, Holtrop G, et al. (2007) Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 73, 1073–1078.
20Russell WR, Gratz S, Duncan SH, et al. (2011) High protein, reduced carbohydrate diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 93, 1062–1072.
21Louis P, Young P, Holtri G, et al. (2010) Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol 12, 304–314.
22Hippe B, Zwielehner J, Liszt K, et al. (2011) Quantification of butyryl CoA-transferase genes reveals different butyrate production capacity in individuals according to diet and age. FEMS Microbiol Lett 316, 130–135.
23Sandler RH, Finegold SM, Bolte ER, et al. (2000) Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 15, 429–435.
24Klinder A, Forster A, Caderni G, et al. (2004) Fecal water genotoxicity is predictive of tumor-preventive activities by inulin-like oligofructoses, probiotics (Lactobacillus rhamnosus and Bifidobacterium lactis) and their synbiotic combination. Nutr Cancer 49, 144–155.
25Cani PD, Amar J, Iglesias MA, et al. (2007) Metabolic endotoxaemia initiates obesity and insulin-resistance. Diabetes 56, 1761–1772.
26Li M, Wang B, Zhang M, et al. (2008) Symbiotic gut microbes modulate human metabolic phenotypes. PNAS 105, 2117–2122.
27Cani PD & Delzenne NM (2009) Interplay between obesity and associated metabolic disorders: new insights in the gut microbiota. Curr Opin Pharmacol 9, 737–743.
28Zhang C, Zhang M, Wang S, et al. (2010) Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndrome in mice. ISME J 4, 232–241.
29Atarashi K, Nishimura J, Shima T, et al. (2008) ATP drives lamina propria TH17 cell differentiation. Nature 455, 808–814.
30Ivanov At II, arashi K, Manel N, et al. (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498.
31Atarashi K, Tanoue T, Shima T, et al. (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337–341.
32Sokol H, Pigneur B, Watterlot L, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS 105, 16731–16736.
33Collins SM & Bercic P (2009) The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136, 2003–2014.
34Spiller R & Garsed K (2009) Postinfectious irritable bowel syndrome. Gastroenterology 136, 1979–1988.
35Barbara G, Stanghellini V, Brandi G, et al. (2005) Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 100, 2560–2568.
36Sudo N, Chida Y, Aiba Y, et al. (2004) Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 1, 263–275.
37O'Mahony SM, Marchesi JR, Scully P, et al. (2008) Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 65, 263–267.
38Schoepfer AM, Schaffer T, Seibold-Schmid B, et al. (2008) Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 20, 1110–1118.
39Preidis GA & Versalovic J (2009) Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136, 2015–2031.
40Moayyedi P, Ford AC, Talley NJ, et al. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59, 325–332.
41Pimentel M, Park S, Mirocha J, et al. (2006) The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145, 557–563.
42Malinen E, Rinttilä T, Kajander K, et al. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100, 373–382.
43Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133, 24–33.
44Lyra A, Rinttilä T, Nikkilä J, et al. (2009) Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 15, 5936–5945.
45Malinen E, Rintatilä T, Kajander K, et al. (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100, 373–382.
46Simrén M & Stotzer PO (2006) Use and abuse of hydrogen breath tests. Gut 55, 297–303.
47Lee H-R & Pimentel M (2006) Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep 8, 305–311.
48Salzman NH, Underwood MA & Bevins CL (2007) Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol 19, 70–83.
49Langhorst J, Junge A, Rueffer A, et al. (2009) Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 104, 404–410.
50Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9, 799–809.
51Piche T, Barbara G, Aubert P, et al. (2009) Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58, 196–201.
52Barbara G, Stanghellini V, De Giorgio R, et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693–702.
53Barbara G, Wang B, Stanghellini V, et al. (2007) Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132, 26–37.
54Spor A, Koren O & Ley R (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9, 279–289.
55Lebeer S, Vanderleyden J & De Keersmaecker SC (2010) Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8, 171–184.
56Abreu M (2010) Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 10, 131–444.
57Haller D, Russo MP, Sartor RB, et al. (2002) IKKβ and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced ReIA phosphorylation and NF-κB activation in both primary and intestinal epithelial cells. J Biol Chem 277, 38168–38178.
58Ruiz PA, Shkoda A, Kim SC, et al. (2005) IL-10 gene-deficient mice lack TGF-β/Smad signalling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonisation with colitogenic Enterococcus faecalis. J Immunol 174, 2990–2999.
59Hoffmann M, Rath E, Holzwimmer G, et al. (2008) Lactobacillus reuteri 100-23 transiently activates intestinal epithelial cells of mice that have a complex microbiota during early stages of colonization. J Nutr 138, 1684–1691.
60Kaser A, Zeissig S & Blumberg RS (2010) Inflammatory bowel disease. Ann Rev Immunol 28, 573–621.
61Steck N, Hoffmann M, Sava IG, et al. (2011) Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 141, 959–971.
62Lebeer S, Vanderleyden J & De Keersmaecker SCJ (2010) Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8, 171–184.
63Clavel T & Haller D (2007) Bacteria- and host-derived mechanisms to control intestinal cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis 13, 1153–1164.
64Werner T, Wagner SJ, Martinez I, et al. (2011) Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 60, 325–333.
65Schiffrin EJ, Rochat F, Link-Amster H, et al. (1995) Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 78, 491–497.
66European Food Safety Authority (2011) Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J 9, 1984.
67Bunout D, Barrera G, Hirsch S, et al. (2004) Effects of a nutritional supplement on the immune response and cytokine production in free-living Chilean elderly. JPEN J Parenter Enteral Nutr 28, 348–354.
68Boge T, Rémigy M, Vaudaine S, et al. (2009) A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 27, 5677–5684.
69Olivares M, Díaz-Ropero MP, Sierra S, et al. (2007) Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition 23, 254–260.
70Davidson LE, Fiorino AM, Snydman DR, et al. (2011) Lactobacillus GG as an immuneadjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr 65, 501–507.
71Van Overtvelt L, Moussu H, Horiot S, et al. (2010) Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine 28, 2986–2992.
72Callegari ML, Riboli B, Sanders JW, et al. (1998) The S-layer gene of Lactobacillus helveticus CNRZ 892: cloning, sequence and heterologous expression. Microbiology 144, 719–726.
73Konstantinov SR, Smidt H, de Vos WM, et al. (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. PNAS 105, 19474–19479.
74Voltan S, Martines D, Elli M, et al. (2008) Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa. Gastroenterology 135, 1216–1227.
75Boyle F & Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Annals Oncol 16, 481–488.
76World Cancer Research Fund/American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington DC: AICR.
77Commane D, Hughes R, Shortt C, et al. (2005) The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mutat Res 591, 276–289.
78Reddy BS (1998) Prevention of colon cancer by pre- and probiotics: evidence from laboratory studies. Br J Nutr 80, S219–S223.
79Kawano A, Ishikawa H, Nakamura T, et al. (2010) Evaluation of epidemiological studies of intestinal bacteria that affected occurrence of colorectal cancer: studies on prevention of colorectal tumours by dairy products and lactic acid bacteria. Nippon Eiseigaku Zasshi 65, 422–446.
80Oberreuther-Moschner DL, Jahreis G, Rechkemmer G, et al. (2004) Dietary intervention with the probiotics Lactobacillus acidophilus 145 and Bifidobacterium longum 913 modulates the potential of human faecal water to induce damage in HT29clone19A cells. Br J Nutr 91, 925–932.
81Ishikawa H, Akedo I, Otani T, et al. (2005) Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumours. Int J Cancer 116, 762–767.
82Femia AP, Luceri C, Dolara P, et al. (2002) Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. Carcinogenesis 23, 1953–1960.
83Rafter J, Bennett M, Caderni G, et al. (2007) Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 85, 488–496.
84Neville V, Gleeson M & Folland JP (2008) Salivary IgA as a risk factor for upper respiratory infections in elite professional athletes. Med Sci Sports Exerc 40, 1228–1236.
85Gleeson M (2007) Exercise and immune function. J Appl Physiol 103, 693–699.
86Nieman DC, Johanssen LM, Lee JW, et al. (1990) Infectious episodes in runners before and after the Los Angeles Marathon. J Sports Med Phys Fitness 30, 316–328.
87Simons SM & Kennedy RG (2004) Gastrointestinal problems in runners. Curr Sports Med Rep 3, 112–116.
88Jeukendrup AE, Vet-Joop K, Sturk A, et al. (2000) Relationship between gastro-intestinal complaints and endotoxaemia, cytokine release and the acute-phase reaction during and after long-distance triathlon in highly trained men. Clin Sci 98, 47–55.
89Kekkonen RA, Vasankari TJ, Vuorimaa T, et al. (2007) The effect of probiotics on respiratory infections and gastrointestinal symptoms during training in marathon runners. Int J Sport Nutr Exerc Metab 7, 352–363.
90Tiollier E, Chennaoui M, Gomez-Merino D, et al. (2007) Effect of a probiotic supplementation on respiratory infections and immune and hormonal parameters during intense military training. Mil Med 172, 1006–1011.
91Cox AJ, Pyne DB, Saunders PU, et al. (2010) Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. Br J Sports Med 44, 222–226.
92Gleeson M, Bishop NC, Oliveira M, et al. (2011) Daily probiotic's (Lactobacillus casei Shirota) reduction of infection incidence in athletes. Int J Sport Nutr Exerc Metab 21, 55–64.